BioCentury | May 16, 2016
Analyst Picks & Changes

Analyst picks & changes

...two patent infringement suits regarding Xyrem sodium oxybate. Jazz granted Wockhardt Ltd. (BSE:532300) and the Ranbaxy...
BioCentury | May 9, 2016
Financial News

QLT withdraws private placement

...when it planned to acquire InSite Vision Inc. The deal was subsequently terminated when the Ranbaxy...
BioCentury | Dec 7, 2015
Company News

InSite, Sun Pharmaceutical deal

...Sun’s Ranbaxy Inc. subsidiary completed its acquisition of ophthalmic company InSite for $0.35 per share or...
BioCentury | Nov 2, 2015
Company News

Cipher, Sun Pharmaceutical, Galephar, Allergan deal

...Cipher, Galephar and Sun’s Ranbaxy Pharmaceuticals Inc. subsidiary granted Allergan non-exclusive rights to commercialize a generic...
...the Lidose delivery system on Dec. 27, 2020. Cipher has rights to Absorica from Galephar. Ranbaxy...
BioCentury | Sep 21, 2015
Company News

InSite, Sun Pharmaceutical deal

...Sun’s Ranbaxy Inc. subsidiary will acquire InSite for $0.35 per share or about $48 million. The...
...agreed to be acquired by QLT Inc. (TSX:QLT; NASDAQ:QLTI, Vancouver, B.C.) for $0.18 per share. Ranbaxy...
...a $2.7 million termination fee to QLT on behalf of InSite. If the acquisition between Ranbaxy...
BioCentury | Aug 18, 2015
Politics & Policy

India allocates $267.8M to improve drug regulation

...of Ranbaxy Laboratories Ltd. 's manufacturing facilities were placed on FDA import alerts due to cGMP violations. Ranbaxy...
BioCentury | Jun 22, 2015
Company News

Epirus, Chemo Group deal

...supplying the product to mAbxience. BOW015 launched in India in November 2014 under a partnership Ranbaxy Laboratories Ltd....
BioCentury | Jun 1, 2015
Company News

Teva neurology news

...the market. The FTC’s suit alleged that Cephalon paid Mylan N.V. (NASDAQ:MYL, Canonsburg, Pa.), the Ranbaxy Laboratories Ltd....
BioCentury | May 29, 2015
Company News

Teva agrees to $1.2B pay-for-delay settlement

...of generics into the market. The FTC's suit, filed in 2008, alleged that Cephalon paid Ranbaxy Laboratories Ltd....
BioCentury | May 4, 2015
Company News

Ranbaxy, Sun Pharmaceutical deal

...will receive 0.8 shares of Sun for every share of Ranbaxy held. The transaction values Ranbaxy...
...and 423.8 million Ranbaxy shares outstanding at March 24, 2014 (see BioCentury, April 14, 2014). Ranbaxy Laboratories Ltd....
Items per page:
1 - 10 of 322
BioCentury | May 16, 2016
Analyst Picks & Changes

Analyst picks & changes

...two patent infringement suits regarding Xyrem sodium oxybate. Jazz granted Wockhardt Ltd. (BSE:532300) and the Ranbaxy...
BioCentury | May 9, 2016
Financial News

QLT withdraws private placement

...when it planned to acquire InSite Vision Inc. The deal was subsequently terminated when the Ranbaxy...
BioCentury | Dec 7, 2015
Company News

InSite, Sun Pharmaceutical deal

...Sun’s Ranbaxy Inc. subsidiary completed its acquisition of ophthalmic company InSite for $0.35 per share or...
BioCentury | Nov 2, 2015
Company News

Cipher, Sun Pharmaceutical, Galephar, Allergan deal

...Cipher, Galephar and Sun’s Ranbaxy Pharmaceuticals Inc. subsidiary granted Allergan non-exclusive rights to commercialize a generic...
...the Lidose delivery system on Dec. 27, 2020. Cipher has rights to Absorica from Galephar. Ranbaxy...
BioCentury | Sep 21, 2015
Company News

InSite, Sun Pharmaceutical deal

...Sun’s Ranbaxy Inc. subsidiary will acquire InSite for $0.35 per share or about $48 million. The...
...agreed to be acquired by QLT Inc. (TSX:QLT; NASDAQ:QLTI, Vancouver, B.C.) for $0.18 per share. Ranbaxy...
...a $2.7 million termination fee to QLT on behalf of InSite. If the acquisition between Ranbaxy...
BioCentury | Aug 18, 2015
Politics & Policy

India allocates $267.8M to improve drug regulation

...of Ranbaxy Laboratories Ltd. 's manufacturing facilities were placed on FDA import alerts due to cGMP violations. Ranbaxy...
BioCentury | Jun 22, 2015
Company News

Epirus, Chemo Group deal

...supplying the product to mAbxience. BOW015 launched in India in November 2014 under a partnership Ranbaxy Laboratories Ltd....
BioCentury | Jun 1, 2015
Company News

Teva neurology news

...the market. The FTC’s suit alleged that Cephalon paid Mylan N.V. (NASDAQ:MYL, Canonsburg, Pa.), the Ranbaxy Laboratories Ltd....
BioCentury | May 29, 2015
Company News

Teva agrees to $1.2B pay-for-delay settlement

...of generics into the market. The FTC's suit, filed in 2008, alleged that Cephalon paid Ranbaxy Laboratories Ltd....
BioCentury | May 4, 2015
Company News

Ranbaxy, Sun Pharmaceutical deal

...will receive 0.8 shares of Sun for every share of Ranbaxy held. The transaction values Ranbaxy...
...and 423.8 million Ranbaxy shares outstanding at March 24, 2014 (see BioCentury, April 14, 2014). Ranbaxy Laboratories Ltd....
Items per page:
1 - 10 of 322